Merck’s Melanoma Drug Wins FDA Accelerated Approval

Drug Industry Daily
A A
The FDA granted Merck’s new melanoma drug Keytruda accelerated approval and orphan drug status after a clinical trial indicated improved efficacy.

To View This Article:

Login

Subscribe To Drug Industry Daily